Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Simulect · 1 trial · 1 indication
CD25 saturation is the percentage of T cells expressing CD25. Mean AUC of CD25 was calculated only for patients who received two Simulect® injections.
CD25 saturation is the percentage of T cells expressing CD25
| Arm | Type | Description |
|---|---|---|
| Simulect 40mg + Neoral + Myfortic + steroids | ACTIVE_COMPARATOR | A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids |
| Simulect 80mg + Neoral + Myfortic + steroids | EXPERIMENTAL | A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids |
| Simulect 80mg + Certican + Myfortic + steroids | EXPERIMENTAL | A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids |
| Name | Type | Description |
|---|---|---|
| Simulect® | DRUG | Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC). |
| Neoral® | DRUG | Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs. |
| Certican® | DRUG | Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs. |
| Myfortic® | DRUG | Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets. |
| Corticosteroids | DRUG | Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day. |
Inclusion Criteria: * Patients receiving a primary renal graft from a deceased or living, related or unrelated donor and who require basiliximab induction therapy * Cold ischemia time \< 30 hours Exclusion (Non inclusion) criteria: * Patients undergoing multi-organ transplantation, including both...
Simulect is used for prophylaxis of acute organ rejection in adult patients receiving renal transplantation. It is administered as an induction therapy in combination with other immunosuppressive agents, such as ciclosporine microemulsion or everolimus, to prevent the immune system from attacking the transplanted kidney.
Simulect targets the alpha chain of the interleukin-2 receptor (CD25) on activated T-lymphocytes. By binding to this receptor, it blocks interleukin-2-mediated activation and proliferation of T-cells, which are key drivers of acute rejection in renal transplant recipients.
Simulect is developed by Novartis AG, a multinational pharmaceutical company headquartered in Basel, Switzerland. Novartis is listed on the New York Stock Exchange under the ticker symbol NVS.
Simulect is in Phase 2 clinical development. A Phase 2 trial, the IDEALE study (NCT01596062), has been completed. This trial evaluated the pharmacodynamics, efficacy, and safety of basiliximab 40 or 80 mg in combination with ciclosporine microemulsion or everolimus in adult low-risk de novo renal transplant recipients.
Simulect has one completed Phase 2 clinical trial, the IDEALE study (NCT01596062), conducted in France. This randomized, active-controlled trial enrolled 16 adult patients aged 18 years and older with renal transplantation. The study evaluated the pharmacodynamics, efficacy, and safety of basiliximab 40 or 80 mg in combination with ciclosporine microemulsion or everolimus.
Yes, Simulect is the brand name for basiliximab. The clinical trial NCT01596062 refers to the drug as basiliximab, confirming that Simulect and basiliximab are the same medication. Basiliximab is a chimeric monoclonal antibody that targets the interleukin-2 receptor alpha chain.